|
Antiviral Drugs Global Market Report 2022: Featuring Key Players AbbVie, GlaxoSmithKline, Merck, Pfizer & More
Tuesday, December 13, 2022
DUBLIN, Dec. 5, 2022 /PRNewswire/ -- The "Antiviral Drugs Market by Mechanism of Action, Target Indication, Type of Drug Target, Type of Therapy and Key Geographies: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
Infectious diseases are known to be one of the top 10 leading causes of deaths, worldwide. In-fact, more than 40 million people are affected by various types of infectious diseases annually. An article published in The Lancet journal reported that COVID-19 alone caused death of over 18 million people in 2020. Further, it has been reported that human immunodeficiency virus (HIV) is anticipated to be the cause for 6.5 million deaths globally, by 2030.
Over the past few years, a number of antiviral drugs targeting a myriad of infectious diseases, including human immunodeficiency virus (HIV) infection, hepatitis, herpes simplex virus (HSV) infection, cytomegalovirus (CMV) infection, influenza, coronavirus infection (COVID-19) and others, have received approvals from various regulatory authorities, globally.
However, it is important to note that, currently, the approved antiviral drugs (around 80) are capable of targeting only 10 of the 220 known viruses that are responsible for causing multiple life threatening infectious diseases in humans. Further, several antiviral drugs are being evaluated across multiple clinical trials for the treatment of various infectious diseases. Moreover, post the onset of the COVID-19 pandemic, extensive research is being conducted to evaluate the safety and efficacy of novel antiviral therapeutics.
The antiviral therapeutic development is fraught with several challenges, including emergence of drug resistance in viruses (as viruses can frequently mutate their genome) and concerns related to drug safety and efficacy. In order to address the aforementioned concerns, several industry stakeholders have been actively leading the R&D efforts for the development of effective antiviral therapeutics against the known viral targets.
The COVID-19 pandemic also exposed the lack of effective antiviral therapeutics that can be used for the treatment of re-emerging or emerging viral diseases; this has created opportunities for the development of novel antiviral drugs that can be effective against multiple viruses. Presently, more than 375 companies are engaged in the development of over 420 early and late-stage antiviral drugs, worldwide.
These stakeholders have established multiple partnerships and collaborations in order to advance the development of various pipeline candidates. Moreover, in order to fund product development initiatives in this domain, various private and public sector investors have invested around USD 5.5 billion across multiple instances. Driven by the increasing demand for safe and effective antivirals, ongoing pace of innovation in this field, recent partnership activity and sufficient financial support from investors, the antiviral drugs market is anticipated to witness substantial growth in the mid to long-term.
Scope of the Report
-- A general overview of the antiviral drugs, along with information on
types of viruses and viral diseases, different mechanism of action of
antiviral drugs and characteristics and advantages offered by the
antiviral drugs. The chapter concludes with a discussion on the
challenges associated with the development of antiviral drugs and future
prospects in this domain.
-- A detailed assessment of the current market landscape of commercially
available antiviral drugs, based on several relevant parameters, such as
year of approval, type of dosage form (tablets, capsules, liquids,
powders and others /unspecified), type of molecule (small molecules,
biologics), type of target virus (DNA virus and RNA virus), route of
administration (oral, intravenous, subcutaneous, intramuscular and
others / unspecified), dosing frequency, mechanism of action (polymerase
inhibition, protease inhibition, reverse transcriptase inhibition,
nonnucleoside reverse transcriptase inhibition, integrase strand
transfer inhibition, nucleoside reverse transcriptase inhibition, NS5A
inhibition, CYP3A inhibition, neuraminidase inhibition, glycoprotein
inhibition, immunostimulation, interferon alpha stimulation and viral
fusion protein inhibition) and target indication (human immunodeficiency
virus infection, hepatitis C infection, hepatitis B infection, herpes
simplex virus infection, influenza virus infection, cytomegalovirus
infection, coronavirus infection, ebolavirus infection and other
indications). In addition, it provides details on the antiviral drug
developers, along with analyses based on their year of establishment,
company size, geographical location and leading players (in terms of
number of approved antiviral drugs).
-- A detailed assessment of the current market landscape of clinical-stage
antiviral drugs, based on several relevant parameters.
-- An analysis of partnerships that have been inked by stakeholders engaged
in this domain, since 2019.
-- A detailed analysis of investments that have been made into companies
engaged in the antiviral drugs domain, since 2019, capturing instances
of venture capital financing, capital raised from IPOs and subsequent
public offerings, grants, debts and other equity.
-- Elaborate profiles of prominent players engaged in development of
antiviral drugs, featuring a brief overview of the company, details on
its product portfolio and recent developments with an informed future
outlook.
Key Players
-- AbbVie
-- AstraZeneca
-- Bristol-Myers Squibb
-- Genentech
-- Gilead Sciences
-- GlaxoSmithKline (GSK)
-- Johnson & Johnson
-- Merck
-- Novartis
-- Pfizer
-- Roche
-- ViiV Healthcare
Key Topics Covered:
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. MARKET LANDSCAPE: APPROVED ANTIVIRAL DRUGS
5. MARKET LANDSCAPE: CLINICAL ANTIVIRAL DRUGS
6. COMPANY PROFILES
7. PARTNERSHIPS AND COLLABORATIONS
8. FUNDING AND INVESTMENTS
9. PORTER'S FIVE FORCES ANALYSIS
10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
For more information about this report visit https://www.researchandmarkets.com/r/9yaamf
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/antiviral-drugs-global-market-report-2022-featuring-key-players-abbvie-glaxosmithkline-merck-pfizer--more-301694773.html
SOURCE Research and Markets
|
|
|
|
|
|
 |
Sup AI Sets New Benchmark Record with 52.15% on Humanity's Last Exam | Jan 22, 2026
|
|
Weekly Recap: 11 Tech Press Releases You Need to See | Jan 22, 2026
|
|
Trigent Partners with WeWork India to Expand its GCC Footprint | Jan 22, 2026
|
|
Skunk Works® and XTEND Expand Joint All Domain Command and Control for Advanced Mission Execution | Jan 22, 2026
|
|
DEADLINE ANNOUNCED FOR 2026 NEW TOP-LEVEL DOMAIN APPLICATIONS | Jan 22, 2026
|
|
Altair HyperWorks 2026 Delivers Design and Simulation at Scale with AI | Jan 22, 2026
|
|
Exia Labs Brings Keystone to the U.S. Navy via DIU's Blue Object Management Challenge | Jan 22, 2026
|
|
Marketing Evolution Announces New Investment Led by Insight Partners to Power AI-Ready Marketing Data for the Agentic Era | Jan 22, 2026
|
|
Glasswall Brings Defense-Level File Sanitization to Every Government Agency and Business Using Microsoft 365 | Jan 22, 2026
|
|
Genpact Named a Leader in ISG Provider Lens(TM) 2025 for Insurance GCCs and Agentic AI Services | Jan 22, 2026
|
|
|
|
